Expert Interviews

Kord Honda, MD, reviews the hormonal drivers of acne, prevention-focused treatment, and common skin care misconceptions.

Raj Chovatiya, MD, PhD, MSCI, co-chair of RAD 2026, highlighted new AD science, type 2 inflammation insights, and emerging therapies—helping clinicians translate immunology advances into better patient care.

Expert guidance from RAD 2026 dispels eczema diet myths, urging symptom-based allergy testing and whole-patient atopic dermatitis care with practical skin, sleep, and lifestyle strategies.

Discover how JAK inhibitors reshape AD care with rapid relief, smart safety screening, and emerging personalized strategies that guide real-world treatment choices.

RNA gene-expression profiling from biopsy stratifies cutaneous squamous cell cancer metastasis risk, guiding surveillance and adjuvant radiation.

Learn when gene expression profiling reshapes cutaneous SCC risk, guiding radiation, imaging, and follow-up beyond traditional staging.

At RAD 2026, Peter Lio, MD, discussed shared decision-making strategies and emerging microbiome-targeted therapies for atopic dermatitis.

Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.

Mona Shahriari, MD, FAAD, urges viewing AD as systemic, guiding earlier personalized systemic therapy while optimizing topicals and shared decision-making

David Rosmarin, MD, reviewed the heterogeneous nature of chronic hand eczema, areas of unmet need in atopic dermatitis treatment, and emerging systemic options in the vitiligo pipeline at RAD 2026.

Adam Friedman, MD, discusses dysbiosis and immune dysfunction in atopic dermatitis and the impact on bacterial and viral infections.

Mona Shahriari, MD, FAAD, shares expert insights on tailoring atopic dermatitis care, from IL‑13 biologics to promising OX40 drugs that may modify disease long term.

At RAD 2026, David Rosmarin, MD, discussed the unmet need in chronic hand eczema, emerging pipeline agents, and his approach to evaluating clinical trial data.

Explore evolving pediatric atopic dermatitis care: personalized, stepwise therapy, early-infant treatment gaps, growth monitoring, and expanding nonsteroidal options promising better outcomes.

Drawing parallels to diabetes and hypertension, Adam Friedman, MD, invokes the dangerous side effect of doing nothing in reframing treatment strategies.

Adam Friedman, MD, maps the AD comorbidity spectrum, from T2-driven diseases to sleep-related indirect consequences, and discusses clinical implications.

Elizabeth Buzney, MD, provides her advice for practice setup, prior authorization timelines, and patient counseling for afamelanotide treatment in erythropoietic protoporphyria.

Microneedle SkinJect patch aims to clear basal cell carcinoma without surgery, showing phase 2 promise and expanding to Gorlin syndrome trials.

Dissolvable microneedles deliver doxorubicin to basal cell lesions, showing promising phase 2 clearance and opening hope for Gorlin syndrome patients.

Michael Ingrassia, PhD, and Ida Wong, MBA, speak about the brand's new line, pairing clinically tested soothing skin care with makeup to calm reactive skin, strengthen the barrier, and ease redness-related stress.

As Darrell Rigel, MD, MS, notes, bemotrizinol will deliver photostable broad-spectrum UVA/UVB protection with better cosmetic feel, low absorption, and pave the way for more advanced US sunscreens.

How 41-gene profiling and ctDNA reshape cutaneous SCC care, guiding radiation, imaging, and tighter follow-up for hidden high-risk tumors.

How 41-gene profiling and ctDNA refine cutaneous SCC risk after Mohs, guiding radiation, imaging, and tighter follow-up.

Learn how today’s aesthetic care is shifting to prevention through skin care, retinoids, lasers, and conservative fillers for natural, refreshed aging.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, discusses early efficacy signals, the phase 2b study design, and the potential clinical role of KT-621, an oral STAT6 degrader, for moderate to severe atopic dermatitis.

Elizabeth Buzney, MD, explains her approach to monitoring patients with erythropoietic protoporphyria using afamelanotide, including skin surveillance, liver function testing, seasonal treatment decisions, and sun protection counseling.

William Posten, MD, provides an overview of postoperative radiation therapy as a treatment for keloids, including dosing parameters, safety considerations, and insurance reimbursement trends.

Amy Snow, MSPAS, PA-C, speaks about her collaboration with wellness influencer to fight TikTok skin care myths and share diet-smart acne tips for teens.

Younger patients are embracing preventative injectables and skin care; Shawna Jones, PA-C, urges evidence-based, personalized plans to cut through social-media hype.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, reviews phase 1b data for KT-621, an oral STAT6 degrader being evaluated for atopic dermatitis.